Argenx Snags First US. FDA Approval With Vyvgart (efgartigimod alfa-fcab) win in Generalized Myasthenia Gravis
Synopsis: VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART…